Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 17/20 | 0.33 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.33 |
| ▸ | PDE1B | Q01064 | 4/20 | 0.33 |
| ▸ | CDK4 | P11802 | 1/20 | 0.32 |
| ▸ | CCND1 | P24385 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13889500 | 1.00 | PDE9A (0.33) | PDE9APDE1CPDE1BCDK4CCND1 | |
| SCHEMBL12601707 | 0.91 | PDE9A (0.34) | PDE9APDE1CPDE1BCDK4CCND1 | |
| SCHEMBL13889498 | 0.91 | PDE9A (0.34) | PDE9APDE1CPDE1BCDK4CCND1 | |
| SCHEMBL889896 | 0.88 | CDK4 (0.34) | PDE9APDE1CPDE1BCDK4CCND1 | |
| SCHEMBL889780 | 0.79 | CDK4 (0.35) | PDE9APDE1CPDE1BCDK4CCND1 | |
| SCHEMBL13889499 | 0.78 | TK2 (0.40) | PDE9APDE1CPDE1BCDK4CCND1 | |
| SCHEMBL12601708 | 0.78 | TK2 (0.40) | PDE9APDE1CPDE1BCDK4CCND1 | |
| SCHEMBL13889495 | 0.74 | POLB (0.37) | — | |
| SCHEMBL12601697 | 0.74 | POLB (0.37) | — | |
| SCHEMBL13166487 | 0.68 | RNASE1 (0.36) | RNASE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943752-B2 | Modified oligonucleotides and applications thereof | Applied Biosystems, L.L.C. (US) | 2011-05-17 | — | — | US | disclosed |
| US-20090226924-A1 | Modified Oligonucleotides and Applications Thereof | APPLERA CORPORATION | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090226924-A1 | Modified Oligonucleotides and Applications Thereof | RNGTT, POLRMT, POLM | PDE9A 3716/4885PDE1C 3742/4885PDE1B 3955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.